Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Adult Severe Sepsis and Septic Shock
2009-017825-21Phase 3Active
- Sponsor
- Instituto Aragonés de Ciencias de la Salud
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of melatonin in sepsis and septic shock (2 arms), sponsored by Instituto Aragonés de Ciencias de la Salud. Primary endpoint: 28-day all-cause mortality. Started Apr 2010; status: active.
02
Drugs
melatonin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2009-017825-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017825-21.